ECRI’s Post

In case you missed it - the #VetScienceWeek24 Preliminary Program is out now👉 https://lnkd.in/gN2SZUNd Check out 3 days of session topics such as: 📌Infectious disease and the eye. 📌Anaesthesia drugs with behavioural implications. 📌Do you suspect pulmonary hypertension? 📌Diagnostic bias: it affects vets too. 📌Cardiac involvement in systemic diseases #ANZCVS #vetscience #VSW24 #VedEducation #Vet

Coronary artery disease stands as a prevalent cause of morbidity and mortality in developed nations. Atherosclerosis, the underlying culprit, leads to coronary artery disease and stroke due to the accumulation of lipids and cholesterol in the arterial walls. Commencing in early childhood, atherosclerosis advances over the course of one's life. Thus, advocating for lipid profile screening in children with congenital heart disease is imperative to mitigate the risk of atherosclerosis. Transasia Bio-Medicals offers Erba HDL and Erba LDL Liquixx reagents, renowned for their high sensitivity and specificity. These cutting-edge solutions ensure timely and accurate detection of cardiac issues, contributing to timely intervention and improved patient outcomes. Learn more on https://zurl.co/kMwP https://zurl.co/YU0A or get in touch: 7304448818. #IAmTransasia #WeAreErba #CHD #coronaryheartdisease #laboratorydiagnosis #bloodtest #clinicalanalysis #LDL #HDL #cholesterol #lipids #biochemistry

⚠ UPDATED GUIDELINE ⚠ Following a review of evidence for people with Covid-19, NICE - National Institute for Health and Care Excellence have released new recommendations related to pulmonary embolism and deep vein thrombosis. https://lnkd.in/e5epPGpu #clinicalguideline #healthcare #covid #covid19

Coronary artery disease stands as a prevalent cause of morbidity and mortality in developed nations. Atherosclerosis, the underlying culprit, leads to coronary artery disease and stroke due to the accumulation of lipids and cholesterol in the arterial walls. Commencing in early childhood, atherosclerosis advances over the course of one's life. Thus, advocating for lipid profile screening in children with congenital heart disease is imperative to mitigate the risk of atherosclerosis. Transasia Bio-Medicals offers Erba HDL and Erba LDL Liquixx reagents, renowned for their high sensitivity and specificity. These cutting-edge solutions ensure timely and accurate detection of cardiac issues, contributing to timely intervention and improved patient outcomes. Learn more on https://zurl.co/kMwP https://zurl.co/YU0A or get in touch: 7304448818. #IAmTransasia #WeAreErba #CHD #coronaryheartdisease #laboratorydiagnosis #bloodtest #clinicalanalysis #LDL #HDL #cholesterol #lipids #biochemistry

Study Spotlight | The PTN has six ongoing studies. One is evaluating the safety of sildenafil, a medicine approved to treat pulmonary hypertension in adults and children ages 1-17, for treating premature infants at risk of bronchopulmonary dysplasia (BPD). BPD is a chronic lung disease that can affect babies born prematurely. Learn more about the study: https://lnkd.in/g_7xzd3f

The efficacy and tolerability concerns surrounding certain migraine prevention treatments have resulted in diminished adherence to oral preventive therapies, underscoring the persistent gap in achieving adequate migraine prevention. Results from a study featured in Headache Journal (Headache: The Journal of Head & Face Pain) led the FDA to clear the Nerivio® REN wearable for acute and/or preventive treatment of migraine with or without aura in patients 12 years of age or older. These research outcomes reinforce the substantial benefits of the Nerivio REN wearable in terms of efficacy, safety, and potential for preventive care in people living with migraine disease. Read the full study: https://lnkd.in/eFEU2zRF

👏#AccScience New Paper Published👇 "#Adenine base editing as a promising #therapy for #cardiovascular diseases" 👥Luzi Yang et al. Read it here #OpenAccess: https://lnkd.in/gH3WjBmD #Translationalmedicine #Medicine #AccScience

Patients with compromised immune systems face unique challenges when dealing with onychomycosis. Let's explore insights from Dr. Emily Johnson, an experienced immunologist on addressing onychomycosis in these particular patients. Early Detection and Diagnosis: Prompt identification of onychomycosis symptoms is crucial in patients with compromised immune systems. Collaborative Approach: Collaboration between foot care professionals and immunologists is essential for comprehensive treatment plans. Tailored Treatment Options: Customized treatments, considering potential interactions with immunosuppressive drugs, are necessary. Preventive Measures: Educating patients about foot hygiene and avoiding high-risk environments is vital. #CompromisedImmuneSystems #ImmunologistInsights

Is AATD hiding behind your patient’s COPD? Alpha-1 is the #1 known genetic risk factor for COPD. On World Lung Day (September 25th), prioritize ruling out a potential underlying cause of COPD and treatment resistant asthma. Although patients with AAT deficiency and COPD share similar symptoms, those with alpha-1 may require a specialized medical plan. AlphaID offers fast, free, and accurate screening. HCPs can order screening kits at https://lnkd.in/d3fFz5Gd For those with COPD, test kits may now be ordered at https://lnkd.in/efc9Rcaj The receipt of this free testing service does not create any expectation or obligation to purchase or use any product or service offered by any manufacturer. #COPDSmokeScreen #Alpha1Awareness #geneticcopd  #alpha1screening #alphaidathome

Inhibitors are antibodies the immune system develops to destroy the factor before it has time to stop the bleeding (seen in the illustration). Developing an inhibitor continues to be one of the most serious and costly complications of hemophilia. Approximately 30 percent of people with severe #hemophilia A, and two to three percent of people with hemophilia B, form an inhibitor to clotting factor; little is known as to why this occurs. One of the key findings of the CDC's six-year inhibitor study was: anyone with hemophilia can form an inhibitor, and everyone (regardless of age or severity) should be tested yearly. Many patients and their families living with an active inhibitor describe their life similar to before effective treatment was available, and face quality of life issues like depression, acute/chronic pain, missed school/work, frequent clinical/hospital visits, problems with venous access, and accelerated joint damage. Treatment of bleeding episodes and inhibitor eradication can be a long and difficult road. Learn more at: https://bit.ly/3IyUnEU